Yi Lin

List of Publications by Citations

224 papers	9,697 citations	40 h-index	97 g-index
235 ext. papers	13,586 ext. citations	5.4 avg, IF	5.69 L-index

#	Paper	IF	Citations
224	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *New England Journal of Medicine*, **2017**, 377, 2531-2544	59.2	2326
223	Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. *Nature Reviews Clinical Oncology*, **2018**, 15, 47-62	19.4	1082
222	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. *Lancet Oncology, The*, **2019**, 20, 31-42	21.7	796
221	Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. *New England Journal of Medicine*, **2019**, 380, 1726-1737	59.2	672
220	Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. *Mayo Clinic Proceedings*, **2013**, 88, 360-76	6.4	341
219	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. *New England Journal of Medicine*, **2021**, 384, 705-716	59.2	287
218	Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. *Prostate*, **2010**, 70, 443-55	4.2	199
217	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. *Journal of Clinical Oncology*, **2020**, 38, 3119-3128	2.2	197
216	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. *Blood*, **2017**, 129, 2111-2119	2.2	181
215	Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. *Blood*, **2011**, 117, 872-81	2.2	178
214	Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. *Neuro-Oncology*, **2010**, 12, 631-44	1	150
213	Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. *Journal of Clinical Oncology*, **2013**, 31, 4319-24	2.2	146
212	Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. *Lancet, The*, **2021**, 398, 314-324	40	118
211	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. *Blood Cancer Journal*, **2018**, 8, 59	7	115
210	IAP antagonists induce anti-tumor immunity in multiple myeloma. *Nature Medicine*, **2016**, 22, 1411-1420	50.5	99
209	Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. *Mayo Clinic Proceedings*, **2017**, 92, 578-598	6.4	88
208	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. *JAMA Oncology*, **2017**, 3, 1257-1265	13.4	82

207	Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. *Blood Advances*, **2020**, 4, 4898-4911	7.8	78
206	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 2305-2321	4.7	68
205	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit ALL. *Nature Reviews Clinical Oncology*, **2018**, 15, 218	19.4	68
204	A method for identification and analysis of non-overlapping myeloid immunophenotypes in humans. *PLoS ONE*, **2015**, 10, e0121546	3.7	67
203	Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience. *Blood*, **2018**, 132, 91-91	2.2	64
202	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. *American Journal of Hematology*, **2015**, 90, 181-6	7.1	60
201	Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy. *Blood*, **2017**, 130, 740-740	2.2	58
200	Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). *British Journal of Haematology*, **2012**, 156, 674-6	4.5	53
199	Clinical Application of Mesenchymal Stem Cells in the Treatment and Prevention of Graft-versus-Host Disease. *Advances in Hematology*, **2011**, 2011, 427863	1.5	52
198	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. *American Journal of Hematology*, **2016**, 91, 1123-1128	7.1	52
197	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. *Bone Marrow Transplantation*, **2019**, 54, 353-367	4.4	51
196	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. *Leukemia*, **2018**, 32, 2240-2249	10.7	49
195	Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14(+)HLA-DR(lo/neg) Cells): The Gateway to Improved Responses. *Frontiers in Immunology*, **2014**, 5, 147	8.4	49
194	Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy. *Blood*, **2019**, 134, 927-927	2.2	48
193	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. *Blood*, **2017**, 130, 1198-1204	2.2	46
192	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. *American Journal of Hematology*, **2018**, 93, 187-194	7.1	45
191	CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma. *Blood*, **2020**, 136, 22-25	2.2	44
190	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. *Mayo Clinic Proceedings*, **2017**, 92, 908-917	6.4	43

189	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrm macroglobulinemia. *Annals of Hematology*, **2018**, 97, 1417-1425	3	43
188	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. *American Journal of Hematology*, **2016**, 91, 1129-1134	7.1	42
187	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. *Blood*, **2017**, 129, 82-87	2.2	41
186	Immune monitoring using the predictive power of immune profiles **2013**, 1, 7		41
185	Immunosuppressive CD14HLA-DR monocytes are elevated in pancreatic cancer and "primed" by tumor-derived exosomes. *OncoImmunology*, **2017**, 6, e1252013	7.2	41
184	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. *American Journal of Hematology*, **2016**, 91, 585-9	7.1	40
183	Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes. *Blood*, **2020**, 136, 25-26	2.2	39
182	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. *Blood Cancer Journal*, **2018**, 8, 116	7	38
181	Cell Damage in Light Chain Amyloidosis: FIBRIL INTERNALIZATION, TOXICITY AND CELL-MEDIATED SEEDING. *Journal of Biological Chemistry*, **2016**, 291, 19813-25	5.4	37
180	Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. *British Journal of Haematology*, **2017**, 179, 50-60	4.5	37
179	Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. *American Journal of Hematology*, **2016**, 91, 984-8	7.1	37
178	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. *Mayo Clinic Proceedings*, **2019**, 94, 472-483	6.4	33
177	Safety and Accuracy of Percutaneous Image-Guided Core Biopsy of the Spleen. *American Journal of Roentgenology*, **2016**, 206, 655-9	5.4	31
176	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. *Circulation: Cardiovascular Imaging*, **2018**, 11, e006588	3.9	31
175	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. *American Journal of Hematology*, **2017**, 92, 50-55	7.1	30
174	Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. *Mayo Clinic Proceedings*, **2016**, 91, 1354-1361	6.4	30
173	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. *Leukemia*, **2019**, 33, 527-531	10.7	30
172	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. *American Journal of Hematology*, **2018**, 93, 179-186	7.1	29

171	Myelomatous Involvement of the Central Nervous System. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 644-654	2	29
170	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. *Annals of Medicine*, **2017**, 49, 545-551	1.5	27
169	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. *Blood Advances*, **2020**, 4, 3509-3519	7.8	27
168	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. *British Journal of Haematology*, **2019**, 187, 588-594	4.5	26
167	Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma. *Clinical Cancer Research*, **2015**, 21, 4224-33	12.9	25
166	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. *American Journal of Hematology*, **2014**, 89, 1051-4	7.1	25
165	Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. *Blood*, **2019**, 134, 245-245	2.2	24
164	Natural history of multiple myeloma with de novo del(17p). *Blood Cancer Journal*, **2019**, 9, 32	7	22
163	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. *American Journal of Hematology*, **2017**, 92, 1146-1155	7.1	22
162	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. *Nephrology Dialysis Transplantation*, **2016**, 31, 1284-9	4.3	21
161	KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. *Blood*, **2021**, 138, 11-22	2.2	21
160	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2020**, 27, 13-16	2.7	21
159	Clinical characteristics and outcomes in biclonal gammopathies. *American Journal of Hematology*, **2016**, 91, 473-5	7.1	20
158	Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium. *Blood*, **2019**, 134, 763-763	2.2	20
157	Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL).. *Journal of Clinical Oncology*, **2017**, 35, 7512-7512	2.2	20
156	Impact of acquired del(17p) in multiple myeloma. *Blood Advances*, **2019**, 3, 1930-1938	7.8	20
155	The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. *Journal of Critical Care*, **2020**, 58, 58-64	4	19
154	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. *Leukemia*, **2020**, 34, 1135-1143	10.7	19

153	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. *Leukemia*, **2018**, 32, 1811-1815	10.7	18
152	Impact of MYD88 mutation status on histological transformation of Waldenstrm Macroglobulinemia. *American Journal of Hematology*, **2020**, 95, 274-281	7.1	18
151	Posttransplant autoimmune encephalitis. *Neurology: Neuroimmunology and NeuroInflammation*, **2018**, 5, e497	9.1	17
150	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. *Blood Cancer Journal*, **2020**, 10, 82	7	17
149	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. *Blood Cancer Journal*, **2018**, 8, 125	7	17
148	Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. *Blood*, **2021**, 137, 1832-1835	2.2	16
147	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. *American Journal of Hematology*, **2020**, 95, 310-315	7.1	16
146	Comparative analysis of staging systems in AL amyloidosis. *Leukemia*, **2019**, 33, 811-814	10.7	15
145	HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. *OncoImmunology*, **2020**, 9, 1744947	7.2	15
144	Predictors of symptomatic hyperviscosity in Waldenstrm macroglobulinemia. *American Journal of Hematology*, **2018**, 93, 1384-1393	7.1	15
143	PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485). *Blood*, **2015**, 126, 834-834	2.2	15
142	Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. *British Journal of Haematology*, **2017**, 178, 888-895	4.5	14
141	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. *American Journal of Hematology*, **2015**, 90, 888-91	7.1	14
140	Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.. *Journal of Clinical Oncology*, **2018**, 36, 3003-3003	2.2	13
139	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma **2020**, 8,		13
138	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. *Blood Cancer Journal*, **2020**, 10, 4	7	12
137	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. *British Journal of Haematology*, **2017**, 179, 98-105	4.5	12
136	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. *Blood Cancer Journal*, **2018**, 8, 70	7	11

135	Strategies for improving the reporting of human immunophenotypes by flow cytometry **2014**, 2, 18		11
134	2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma. *Blood*, **2018**, 132, 2967-2967	2.2	11
133	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. *American Journal of Hematology*, **2017**, 92, 435-440	7.1	10
132	Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. *Journal of Internal Medicine*, **2017**, 281, 611-619	10.8	10
131	Immune independent crosstalk between lymphoma and myeloid suppressor CD14HLA-DR monocytes mediates chemotherapy resistance. *OncoImmunology*, **2015**, 4, e996470	7.2	9
130	Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells. *Leukemia*, **2020**, 34, 1383-1393	10.7	9
129	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. *Clinical Cancer Research*, **2020**, 26, 6581-6588	12.9	9
128	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. *Haematologica*, **2016**, 101, 1102-9	6.6	9
127	Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. *British Journal of Haematology*, **2021**, 193, 380-385	4.5	9
126	Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life. *Blood*, **2019**, 134, 794-794	2.2	8
125	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. *Blood*, **2015**, 126, 3050-3050	2.2	8
124	Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. *Nature Communications*, **2020**, 11, 5173	17.4	8
123	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. *Blood Cancer Journal*, **2021**, 11, 50	7	8
122	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. *Mayo Clinic Proceedings*, **2021**, 96, 1546-1577	6.4	8
121	Mesenchymal stromal cells protect human cardiomyocytes from amyloid fibril damage. *Cytotherapy* , **2017**, 19, 1426-1437	4.8	7
120	PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter© Transformation: An Updated Report from a Phase 2 Trial (MC1485). *Blood*, **2016**, 128, 4392-4392	2.2	7
119	Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement. *Mayo Clinic Proceedings*, **2019**, 94, 2361-2364	6.4	7
118	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. *American Journal of Hematology*, **2019**, 94, 751-756	7.1	6

117	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. *American Journal of Hematology*, **2020**, 95, 637-642	7.1	6
116	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. *Blood*, **2012**, 120, 3972-3972	2.2	6
115	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. *Leukemia*, **2018**, 32, 1421-1426	10.7	5
114	Danhong Promotes Angiogenesis in Diabetic Mice after Critical Limb Ischemia by Activation of CSE-H 2 S-VEGF Axis. *Evidence-based Complementary and Alternative Medicine*, **2015**, 2015, 276263	2.3	5
113	Does Bridging Radiation Therapy Affect the Pattern of Failure After CAR T-cell Therapy in Non-Hodgkin Lymphoma?. *Radiotherapy and Oncology*, **2021**,	5.3	5
112	A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma. *Blood*, **2019**, 134, 4095-4095	2.2	5
111	Health-Related Quality of Life in the Cartitude-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma. *Blood*, **2020**, 136, 41-42	2.2	5
110	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). *Blood*, **2015**, 126, 1774-1774	2.2	5
109	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. *Blood*, **2015**, 126, 4197-4197	2.2	5
108	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. *Leukemia*, **2021**,	10.7	5
107	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 53-56	2	5
106	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2019**, 26, 101-102	2.7	4
105	A simple additive staging system for newly diagnosed multiple myeloma.. *Blood Cancer Journal*, **2022**, 12, 21	7	4
104	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma. *Blood*, **2019**, 134, 4106-4106	2.2	4
103	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. *Mayo Clinic Proceedings*, **2021**, 96, 677-687	6.4	4
102	Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies.. *European Heart Journal*, **2022**,	9.5	4
101	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 40-41	2.7	3
100	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. *American Journal of Hematology*, **2017**, 92, E507-E512	7.1	3

99	Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel). *Blood*, **2020**, 136, 40-42	2.2	3
98	Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study. *Blood*, **2020**, 136, 45-46	2.2	3
97	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). *Blood*, **2016**, 128, 2968-2968	2.2	3
96	Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium. *Blood*, **2021**, 138, 744-744	2.2	3
95	Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).. *Journal of Clinical Oncology*, **2021**, 39, 7552-7552	2.2	3
94	Systematic Review of Risk factors and Incidence of Acute Kidney Injury Among Patients Treated with CAR-T Cell Therapies. *Kidney International Reports*, **2021**, 6, 1416-1422	4.1	3
93	Lines of therapy before autologous stem cell transplant and CAR-T affect outcomes in aggressive Non-Hodgkin© lymphoma. *American Journal of Hematology*, **2021**, 96, E386-E389	7.1	3
92	The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T-cell therapy. *American Journal of Hematology*, **2021**, 96, E399-E402	7.1	3
91	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. *American Journal of Hematology*, **2021**, 96, 446-454	7.1	3
90	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. *Blood*, **2019**, 134, 4386-4386	2.2	2
89	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). *Blood*, **2020**, 136, 30-31	2.2	2
88	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). *Blood*, **2020**, 136, 12-13	2.2	2
87	Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin© Lymphoma (NHL). *Blood*, **2020**, 136, 29-30	2.2	2
86	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. *Blood*, **2013**, 122, 3117-3117	2.2	2
85	Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).. *Journal of Clinical Oncology*, **2021**, 39, 7002-7002	2.2	2
84	Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.. *Journal of Clinical Oncology*, **2021**, 39, 8036-8036	2.2	2
83	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 451-460.e2	2	2
82	Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT.. *Journal of Hematology and Oncology*, **2022**, 15, 36	22.4	2

81	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 44-45	2.7	1
80	Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. *American Journal of Hematology*, **2018**, 93, 1207-1210	7.1	1
79	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. *Blood*, **2019**, 134, 72-72	2.2	1
78	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. *Blood*, **2019**, 134, 4334-4334	2.2	1
77	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). *Blood*, **2020**, 136, 7-8	2.2	1
76	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. *Blood*, **2012**, 120, 946-946	2.2	1
75	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. *Blood*, **2013**, 122, 3095-3095	2.2	1
74	Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era. *Blood*, **2015**, 126, 3992-3992	2.2	1
73	Trends in survival of patients with primary plasma cell leukemia: A population-based analysis from 1973 to 2010.. *Journal of Clinical Oncology*, **2014**, 32, 8608-8608	2.2	1
72	Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. *American Journal of Hematology*, **2021**,	7.1	1
71	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. *Blood*, **2021**, 138, 2527-2527	2.2	1
70	Systemic misfolding of immunoglobulins in the test tube and in the cell. *FASEB Journal*, **2018**, 32, 247.3	0.9	1
69	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. *Blood*, **2018**, 132, 2884-2884	2.2	1
68	Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel). *Blood*, **2019**, 134, 5343-5343	2.2	1
67	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. *Blood*, **2019**, 134, 1800-1800	2.2	1
66	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. *Blood*, **2019**, 134, 5490-5490	2.2	1
65	Novel Mutations in NOTCH and Altered Wnt/β-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia. *Blood*, **2016**, 128, 4103-4103	2.2	1
64	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. *American Journal of Hematology*, **2020**, 95, E60-E62	7.1	1

63	Predictors of short-term survival in Waldenström Macroglobulinemia. *Leukemia and Lymphoma*, **2020**, 61, 2975-2979	1.9	1
62	Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study. *Critical Care Medicine*, **2021**,	1.4	1
61	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type. *Hematological Oncology*, **2021**, 39, 658-663	1.3	1
60	Peak Absolute Lymphocyte Count After CAR-T Infusion Predicts Clinical Response in Aggressive Lymphoma.. *American Journal of Hematology*, **2022**,	7.1	1
59	Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma.. *Current Treatment Options in Oncology*, **2022**, 23, 171	5.4	1
58	Response to Bridging Therapy (BT) before CAR-T Cell Infusion Predicts Outcomes for Relapsed/Refractory (R/R) Aggressive B-Cell Non-Hodgkin Lymphoma (NHL). *Blood*, **2020**, 136, 30-30	2.2	0
57	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. *Blood*, **2020**, 136, 31-32	2.2	0
56	Next generation sequencing (NGS) to identify relapsed gastrointestinal (GI) solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future logic-gated CAR T therapy to reduce on target off tumor toxicity.. *Journal of Clinical Oncology*, **2022**, 40, 190-190	2.2	0
55	Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience.. *Leukemia and Lymphoma*, **2022**, 1-6	1.9	0
54	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. *Blood*, **2020**, 136, 48-49	2.2	0
53	Depth of Response in Waldenstrom Macroglobulinemia. *Blood*, **2018**, 132, 4141-4141	2.2	0
52	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.. *Journal of Clinical Oncology*, **2021**, 39, e19547-e19547	2.2	0
51	Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma.. *Journal of Clinical Oncology*, **2021**, 39, 7554-7554	2.2	0
50	Characteristics, outcomes, and risk factors of ICANS after axicabtagene ciloleucel: Does age matter?. *Journal of Clinical Oncology*, **2021**, 39, e19556-e19556	2.2	0
49	Outcomes in mantle cell lymphoma with central nervous system involvement.. *Journal of Clinical Oncology*, **2021**, 39, e19527-e19527	2.2	0
48	The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. *Blood Cancer Journal*, **2021**, 11, 124	7	0
47	Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel. *American Journal of Hematology*, **2021**, 96, E427-E430	7.1	0
46	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS).. *Blood Cancer Journal*, **2022**, 12, 62	7	0

45	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. *Blood*, **2020**, 136, 27-28	2.2
44	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. *Blood*, **2020**, 136, 9-10	2.2
43	The Utility of Granulocyte Colony Stimulating Factor in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy with Axicabtagene Ciloleucel. *Blood*, **2020**, 136, 23-25	2.2
42	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. *Blood*, **2020**, 136, 44-45	2.2
41	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. *Blood*, **2020**, 136, 15-16	2.2
40	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. *Blood*, **2020**, 136, 6-7	2.2
39	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). *Blood*, **2020**, 136, 21-22	2.2
38	Comparative Analysis of Staging Systems in AL Amyloidosis. *Blood*, **2018**, 132, 3228-3228	2.2
37	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. *Blood*, **2018**, 132, 622-622	2.2
36	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. *Blood*, **2018**, 132, 4449-4449	2.2
35	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. *Blood*, **2018**, 132, 3226-3226	2.2
34	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. *Blood*, **2018**, 132, 3227-3227	2.2
33	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. *Blood*, **2018**, 132, 4615-4615	2.2
32	Patient-Reported Outcome Driven Case Management System for Hematology – a Prospective Study. *Blood*, **2018**, 132, 719-719	2.2
31	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. *Blood*, **2019**, 134, 1532-1532	2.2
30	Characteristics of Patients with Relapsed/Refractory Burkitt Non-Hodgkin Lymphoma (NHL): Impact on the Feasibility of CAR-T Cell Therapy. *Blood*, **2019**, 134, 5352-5352	2.2
29	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2019**, 134, 5833-5833	2.2
28	Central Nervous System Involvement in Peripheral T-Cell Lymphoma. *Blood*, **2019**, 134, 5293-5293	2.2

27	Presence and function of CD14+CD16-HLADRlow monocytes in the peripheral blood of patients with Ecell non-Hodgkin lymphoma (NHL).. *Journal of Clinical Oncology*, **2014**, 32, e19539-e19539	2.2
26	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). *Blood*, **2015**, 126, 3292-3292	2.2
25	Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial. *Blood*, **2015**, 126, 3039-3039	2.2
24	AL Amyloidosis and Patient Reported Quality of Life. *Blood*, **2015**, 126, 3317-3317	2.2
23	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. *Blood*, **2016**, 128, 3273-3273	2.2
22	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. *Blood*, **2016**, 128, 3251-3251	2.2
21	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. *Blood*, **2016**, 128, 3306-3306	2.2
20	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. *Blood*, **2016**, 128, 1194-1194	2.2
19	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. *Blood*, **2016**, 128, 3269-3269	2.2
18	Outcome of Very Young (40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. *Blood*, **2016**, 128, 5576-5576	2.2
17	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. *Blood*, **2012**, 120, 448-448	2.2
16	Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma. *Blood*, **2012**, 120, 1988-1988	2.2
15	Implications of rapidity of response to initial therapy in multiple myeloma.. *Journal of Clinical Oncology*, **2013**, 31, 8606-8606	2.2
14	Definition of a high-risk population among patients with AL amyloidosis not undergoing autologous stem cell transplantation using bone marrow plasmacytosis and the presence of CRAB.. *Journal of Clinical Oncology*, **2013**, 31, 8516-8516	2.2
13	Continued monoclonal protein response beyond day 100 after auto-transplantation for multiple myeloma.. *Journal of Clinical Oncology*, **2013**, 31, 8587-8587	2.2
12	Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien. *Blood*, **2013**, 122, 2151-2151	2.2
11	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. *Blood*, **2013**, 122, 1979-1979	2.2
10	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. *Blood*, **2013**, 122, 3209-3209	2.2

9	Tumor Monocyte Cross Talk Promotes Chemotherapy Resistance In Lymphoma. *Blood*, **2013**, 122, 1774-1774	2.7
8	Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. *European Journal of Haematology*, **2021**, 107, 48-53	3.8
7	Prognostic role of lymphocyte to monocyte ratio in patients treated with CAR-T for aggressive lymphoma.. *Journal of Clinical Oncology*, **2021**, 39, 7558-7558	2.2
6	Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis.. *Journal of Clinical Oncology*, **2021**, 39, 7542-7542	2.2
5	Vaccine titers in lymphoma patients receiving chimeric antigen receptor T-cell therapy.. *Journal of Clinical Oncology*, **2021**, 39, 7555-7555	2.2
4	Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).. *Journal of Clinical Oncology*, **2021**, 39, e20016-e20016	2.2
3	The impact of body weight and body mass index on outcomes of diffuse large B-cell lymphoma treated with axicabtagene ciloleucel.. *Journal of Clinical Oncology*, **2021**, 39, e19554-e19554	2.2
2	Preventive Effects of Epinephrine for Critically Ill Patients? More Questions Waiting to Be Answered. *Digestive Diseases and Sciences*, **2019**, 64, 283-284	4
1	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care.. *JCO Oncology Practice*, **2022**, OP2100789	2.3